The short version of receptor agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-14. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The Second Collier Ministry was the 18th Ministry of the Government of Western Australia and was led by Labor Premier Philip Collier. It succeeded the Second Mitchell Ministry on 24 April 1933, following the defeat of the Nationalist government at the 1933 election on 8 April. The ministry was followed by the Willcock Ministry on 27 August 1936, a week after Collier resigned as Premier on the grounds of ill health and handed over to the Deputy Premier, John Willcock. The following ministers served until the reconstitution of the ministry on 26 March 1935:
OHPH, also known as hydroxyprogesterone enanthate (OHPE), as well as 17α-hydroxyprogesterone heptanoate or 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. It is a progestogen ester; specifically, it is the C17α heptanoate (enanthate) ester of 17α-hydroxyprogesterone. Analogues of OHPH include the more well-known medications hydroxyprogesterone acetate and hydroxyprogesterone caproate (hydroxyprogesterone hexanoate). The C3 benzilic acid hydrazone of OHPH, hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), is known and has been studied in animals. In terms of chemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one additional carbon in its fatty acid ester chain.
Since the fraction of nuclides decaying per unit of time is inversely proportional to an isotope's half-life, the relative radioactivity of the lesser amount of human-produced radioisotopes (thousands of tons instead of trillions of tons) would diminish once the isotopes with far shorter half-lives than the bulk of natural radioisotopes decayed. In January 2013, Cumbria county council rejected UK central government proposals to start work on an underground storage dump for nuclear waste near to the Lake District National Park. "For any host community, there will be a substantial community benefits package and worth hundreds of millions of pounds" said Ed Davey, Energy Secretary, but nonetheless, the local elected body voted 7–3 against research continuing, after hearing evidence from independent geologists that "the fractured strata of the county was impossible to entrust with such dangerous material and a hazard lasting millennia." Horizontal drillhole disposal describes proposals to drill over one km vertically, and two km horizontally in the earth's crust, for the purpose of disposing of high-level waste forms such as spent nuclear fuel, Caesium-137, or Strontium-90. After the emplacement and the retrievability period, drillholes would be backfilled and sealed. A series of tests of the technology were carried out in November 2018 and then again publicly in January 2019 by a U.S. based private company. The test demonstrated the emplacement of a test-canister in a horizontal drillhole and retrieval of the same canister.
== Critical reception == Thomas's work and stature as a poet have been much debated by critics and biographers since his death. Critical studies have been clouded by Thomas's personality and mythology, especially his drunken persona and death in New York. When Seamus Heaney gave an Oxford lecture on the poet he opened by addressing the assembly, "Dylan Thomas is now as much a case history as a chapter in the history of poetry", querying how "Thomas the Poet" is one of his forgotten attributes. The Poetry Archive notes that "Dylan Thomas's detractors accuse him of being drunk on language as well as whiskey, but whilst there's no doubt that the sound of language is central to his style, he was also a disciplined writer who re-drafted obsessively". David Holbrook, who has written three books about Thomas, stated in his 1962 publication Llareggub Revisited, "the strangest feature of Dylan Thomas's notoriety—not that he is bogus, but that attitudes to poetry attached themselves to him which not only threaten the prestige, effectiveness and accessibility to English poetry but also destroyed his true voice and, at last, him." Holbrook's negative evaluation of Thomas's work, based on an ad hominem psychoanalytic reading, is rejected by Rhian Barfoot as reductive and outdated viewed in the context of more recent psychoanalytic theory as found in the work of Lacan and Kristeva, where the emphasis on the semiotic and the materiality of language is seen as corresponding to Thomas's poetic style and thus supportive of a positive critical evaluation of his work.
Sources: en.wikipedia.org
=== Photodetector === A graphene/n-type silicon heterojunction has been demonstrated to exhibit strong rectifying behavior and high photoresponsivity. By introducing a thin interfacial oxide layer, the dark current of graphene/n-Si heterojunction has been reduced by two orders of magnitude at zero bias. At room temperature, the graphene/n-Si photodetector with interfacial oxide exhibits a specific detectivity up to 5.77 × 1013 cm Hz1/2 W2 at the peak wavelength of 890 nm in vacuum. In addition, the improved graphene/n-Si heterojunction photodetectors possess high responsivity of 0.73 A W−1 and high photo-to-dark current ratio of ≈107. These results demonstrate that graphene/Si heterojunction with interfacial oxide is promising for the development of high detectivity photodetectors. Recently, a graphene/si Schottky photodetector with record-fast response speed (< 25 ns) from wavelength 350 nm to 1100 nm are presented. The photodetectors exhibit excellent long-term stability even stored in air for more than 2 years. These results not only advance the development of high-performance photodetectors based on the graphene/Si Schottky junction, but also have important implications for mass-production of graphene-based photodetector array devices for cost-effective environmental monitoring, medical images, free-space communications, photoelectric smart-tracking, and integration with CMOS circuits for emerging interest-of-things applications, etc.
==== AP1 ==== Activation of AP1 factor involves three MAPK signaling pathways. These pathways use a phosphorylation cascade of three successive acting protein kinases to transmit a signal. The three MAPK pathways in T cells involve kinases of different specificities belonging to each of the MAP3K, MAP2K, MAPK families. Initial activation is done by the GTPase Ras or Rac which phosphorylate the MAP3K. A cascade involving the enzymes Raf, MEK1, ERK results in the phosphorylation of Jun, conformational change allows Jun to bind to Fos and hence AP-1 to form. AP-1 then acts as transcription factor. Raf is activated via the second messenger DAG, SOS, and Ras. DAG recruits among other proteins the RAS guanyl nucleotide-releasing protein (RasGRP), a guanine nucleotide exchange factor (GEF), to the membrane. RasGRP activates the small GTPase Ras by exchanging guanosine diphosphate (GDP) bound to Ras against guanosine triphosphate (GTP). Ras can also be activated by the guanine nucleotide exchange factor SOS which binds to the LAT signalosome. Ras then initiates the MAPK cascade. The second MAPK cascade with MEKK1, JNKK, JNK induces protein expression of Jun. Another cascade, also involving MEKK1 as MAPK3, but then activating MKK3 /6 and p38 induces Fos transcription. Activation of MEKK1, additionally to being activated by Ras, involves Slp-76 recruiting the GEF Vav to the LAT signalosome, which then activates the GTPase Rac. Rac and Ras activate MEKK1 and thereby initiate the MAPK cascade.
IUPAC organic nomenclature has three main parts: the substituents, carbon chain length, and chemical affix. The substituents are any functional groups tied to the main carbon chain. The main carbon chain is the longest possible continuous chain. The chemical affix denotes what type of molecule it is. For example, the ending ane conveys a single bonded carbon chain, as in "hexane" (C6H14). Another example of IUPAC organic nomenclature is cyclohexanol:
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.